Cue Biopharma (NASDAQ:CUE) Announces Earnings Results

Cue Biopharma (NASDAQ:CUE) announced its quarterly earnings data on Thursday. The company reported ($1.08) EPS for the quarter, FiscalAI reports. The firm had revenue of $5.69 million for the quarter. Cue Biopharma had a negative return on equity of 165.19% and a negative net margin of 96.85%.

Cue Biopharma Trading Down 15.6%

Shares of NASDAQ:CUE traded down $3.94 during trading on Friday, hitting $21.39. 63,948 shares of the stock were exchanged, compared to its average volume of 512,574. Cue Biopharma has a 12-month low of $4.97 and a 12-month high of $41.42. The company has a market cap of $84.26 million, a PE ratio of -2.23 and a beta of 2.37. The company has a fifty day moving average price of $231.49 and a two-hundred day moving average price of $336.55.

Hedge Funds Weigh In On Cue Biopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CUE. Stifel Financial Corp lifted its position in shares of Cue Biopharma by 25.4% in the fourth quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock valued at $75,000 after acquiring an additional 50,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in Cue Biopharma by 730.0% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after purchasing an additional 73,000 shares during the last quarter. Squarepoint Ops LLC purchased a new position in Cue Biopharma in the 3rd quarter valued at about $62,000. Boothbay Fund Management LLC boosted its stake in shares of Cue Biopharma by 15.3% during the 4th quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock worth $215,000 after purchasing an additional 93,333 shares during the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc boosted its stake in shares of Cue Biopharma by 1,231.2% during the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock worth $135,000 after purchasing an additional 407,568 shares during the last quarter. Institutional investors and hedge funds own 35.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on CUE shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Cue Biopharma in a report on Friday, March 27th. Wall Street Zen raised Cue Biopharma from a “buy” rating to a “strong-buy” rating in a report on Monday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Cue Biopharma presently has an average rating of “Sell”.

Cue Biopharma Company Profile

Cue Biopharma is a clinical?stage biotechnology company focused on the development of next?generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen?specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early?stage clinical studies.